Relationship between NMDA receptor expression and MPP+ toxicity in cultured dopaminergic cells

Journal of Neuroscience Research

Volumn 73, Issue 6, 2003, Pages 811-817

  Church, William H ^a   Hewett, Sandra J ^b  

^a TRINITY COLLEGE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cell culture; Excitotoxicity; Mouse; NMDA receptors; Parkinson's disease; Ventral mesencephalon

Indexed keywords

METHYLPHENYLPYRIDINIUM; N METHYL DEXTRO ASPARTIC ACID R1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PYRIDINIUM DERIVATIVE; RECEPTOR SUBUNIT; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; EMBRYO; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; MESENCEPHALON; MOUSE; NERVE CELL CULTURE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; CELL DEATH; CELLS, CULTURED; DIZOCILPINE MALEATE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; MESENCEPHALON; MICE; MICE, INBRED STRAINS; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS; TRANS-ACTIVATORS; TYROSINE 3-MONOOXYGENASE;

EID: 0041837546     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10732     Document Type: Article

References (59)

1. Andreeva N, Heldt J, Leclerc N, Gross J. 2001. Differential response of immature and mature neurons to hypoxia in rat mesencephalic cultures. Dev Neurosci 23:406-411.
2. Beal MF. 1998. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 44(Suppl):110-114.
3. Bywood PT, Johnson SM. 2003. Mitochondrial complex inhibitors preferentially damage substantia nigra dopamine neurons in rat brain slices. Exp Neurol 179:47-59.
4. Carboni S, Melis F, Pani L, Hadjiconstantinou M, Rossetti ZL. 1990. The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+). Neurosci Lett 117:129-133.
5. Casper D, Mytilineou C, Blurn M. 1991. EGF enhances the survival of dopamine neurons in rat embryonic mesencephalon primary cell culture. J Neurosci Res 30:372-381.
6. Chan P, Langston JW, Di Monte DA. 1993. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. J Pharmacol Exp Ther 267:1515-1520.
7. Cheng C, Fass DM, Reynolds IJ. 1999. Emergence of excitotoxicity in cultured forebrain neurons coincides with larger glutamate-stimulated [Ca(2+)](i) increases and NMDA receptor mRNA levels. Brain Res 849:97-108.
8. Christmann B, Uliasz TF, Hewett SJ. 2002. Developmental expression of NMDA receptors in primary cortical cell culture: relationship to function and excitotoxicity. J Neurochem 81:28-29.
9. Church WH, Hewett SJ. 2002. The relationship between NR1 subunit expression and MPP+ neurotoxicity in cultured dopaminergic neurons. Soc Neurosci Abstr 28:485.
10. Danias P, Nicklas WJ, Ofori S, Shen J, Mytilineou C. 1989. Mesencephalic dopamine neurons become less sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity during development in vitro. J Neurochem 53:1149-1155.
11. Di Monte DA, Lavasani M, Manning-Bog AB. 2002. Environmental factors in Parkinson's disease. Neurotoxicology 23:487-502.
12. Driscoll BF, Law MJ, Crane AM. 1991. Cell damage associated with changing the medium of mesencephalic cultures in serum-free medium is mediated via N-methyl-D-aspartate receptors. J Neurochem 56:1201-1206.
13. Driscoll BF, Deibler GE, Law MJ, Crane AM. 1993. Damage to neurons in culture following medium change: role of glutamine and extracellular generation of glutamate. J Neurochem 61:1795-1800.
14. Finiels-Marlier F, Marini AM, Williams P, Paul SM. 1993. The N-methyl-D-aspartate antagonist MK-801 fails to protect dopaminergic neurons from 1-methyl-4-phenylpyridinium toxicity in vitro. J Neurochem 60:1968-1971.
15. Fornai F, Vaglini F, Maggio R, Bonuccelli U, Corsini GU. 1997. Species differences in the role of excitatory amino acids in experimental parkinsonism. Neurosci Biobehav Rev 21:401-415.
16. Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, Bereznai B, Fabrizio E, Vieregge P, Horstmann RD. 1998. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 18:262-265.
17. Greenamyre JT, MacKenzie G, Peng TI, Stephans SE. 1999. Mitochondrial dysfunction in Parkinson's disease. Biochem Soc Symp 66:85-97.
18. Gwinn-Hardy K. 2002. Genetics of parkinsonism. Mov Disord 17:645-656.
19. Jenner P, Olanow CW. 1998. Understanding cell death in Parkinson's disease. Ann Neurol 44(Suppl):72-84.
20. Johannessen JN, Chiueh CC, Burns RS, Markey SP. 1985. Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci 36:219-224.
21. Johnson SW, Seutin V, North RA. 1992. Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. Science 258:665-667.
22. Katsuki H, Shibata H, Takenaka C, Kume T, Akaike A. 2002. Contribution of NMDA receptor activation to the maintenance of midbrain dopaminergic neurons. Soc Neurosci Abstr 194:20.
23. Kikuchi S, Kim SU. 1993. Glutamate neurotoxicity in mesencephalic dopaminergic neurons in culture. J Neurosci Res 36:558-569.
24. Koller W, Vetere-Overfield B, Gray C, Alexander C, Chin T, Dolezal J, Hassanein R, Tanner C. 1990. Environmental risk factors in Parkinson's disease. Neurology 40:1218-1221.
25. Langston JW. 1987. MPTP: insights into the etiology of Parkinson's disease. Eur Neurol 26(Suppl):2-10.
26. Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
27. Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, Vassilatis DK. 2003. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 33:85-89.
28. Leist M, Fava E, Montecucco C, Nicotera P. 1997. Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity. Eur J Neurosci 9:1488-1498.
29. Leist M, Volbracht C, Fava E, Nicotera P. 1998. 1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis. Mol Pharmacol 54:789-801.
30. Lim KL, Dawson VL, Dawson TM. 2002. The genetics of Parkinson's disease. Curr Neurol Neurosci Rep 2:439-446.
31. Lotharius J, Dugan LL, O'Malley KL. 1999. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci 19:1284-1293.
32. Marey-Semper I, Gelman M, Levi-Strauss M. 1995. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J Neurosci 15:5912-5918.
33. Marsden CD, Olanow CW. 1998. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann Neurol 44(Suppl):189-196.
34. McNaught KS, Jenner P. 1999. Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. J Neurochem 73:2469-2476.
35. Michel PP, Agid Y. 1992. The glutamate antagonist, MK-801, does not prevent dopaminergic cell death induced by the 1-methyl-4-phenylpyridinium ion (MPP+) in rat dissociated mesencephalic cultures. Brain Res 597:233-240.
36. Mizuno Y, Ikebe S, Hattori N, Nakagawa-Hattori Y, Mochizuki H, Tanaka M, Ozawa T. 1995. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim Biophys Acta 1271:265-274.
37. Mytilineou C, Friedman L. 1988. Studies on the metabolism and toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in cultures of embryonic rat mesencephalon. J Neurochem 51:750-755.
38. Nicklas WJ, Vyas I, Heikkila RE. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36:2503-2508.
39. Paquet M, Tremblay M, Soghomonian JJ, Smith Y. 1997. AMPA and NMDA glutamate receptor subunits in midbrain dopaminergic neurons in the squirrel monkey: an immunohistochemical and in situ hybridization study. J Neurosci 17:1377-1396.
40. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
41. Rodriguez MC, Obeso JA, Olanow CW. 1998. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44(Suppl):175-188.
42. Santiago M, Venero JL, Machado A, Cano J. 1992. In vivo protection of striatum from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Brain Res 586:203-207.
43. Saporito MS, Heikkila RE, Youngster SK, Nicklas WJ, Geller HM. 1992. Dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium analogs in cultured neurons: relationship to the dopamine uptake system and inhibition of mitochondrial respiration. J Pharmacol Exp Ther 260:1400-1409.
44. Sawada H, Shimohama S, Tamura Y, Kawamura T, Akaike A, Kimura J. 1996. Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon. J Neurosci Res 43:55-62.
45. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-827.
46. Schinelli S, Zuddas A, Kopin IJ, Barker JL, Di Porzio U. 1988. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolism and 1-methyl-4-phenylpyridinium uptake in dissociated cell cultures from the embryonic mesencephalon. J Neurochem 50:1900-1907.
47. Schubert D, Piasecki D. 2001. Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. J Neurosci 21:7455-7462.
48. Simon DK, Standaert DG. 1999. Neuroprotective therapies. Med Clin North Am 83:509-523.
49. Sonsalla PK, Albers DS, Zeevalk GD. 1998. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids 14:69-74.
50. Sonsalla PK, Nicklas WJ, Heikkila RE. 1989. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243:398-400.
51. Sonsalla PK, Riordan DE, Heikkila RE. 1991. Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J Pharmacol Exp Ther 256:506-512.
52. Sonsalla PK, Zeevalk GD, Manzino L, Giovanni A, Nicklas WJ. 1992. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J Neurochem 58:1979-1982.
53. Srivastava R, Brouillet E, Beal MF, Storey E, Hyman BT. 1993. Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiol Aging 14:295-301.
54. Storey E, Hyman BT, Jenkins B, Brouillet E, Miller JM, Rosen BR, Beal MF. 1992. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 58:1975-1978.
55. Tanner CM, Langston JW. 1990. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 40(Suppl):17-30. Tipton KF, Singer TP. 1993. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191-1206.
56. Trackey JL, Uliasz TF, Hewett SJ. 2001. SIN-1-induced cytotoxicity in mixed cortical cell culture: peroxynitrite-dependent and -independent induction of excitotoxic cell death. J Neurochem 79:445-455.
57. Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H. 1991. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349:414-418.
58. Zeevalk GD, Derr-Yellin E, Nicklas WJ. 1995. NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3-nitropropionic acid. J Neurochem 64:455-458.
59. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU. 1992. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine-induced parkinsonism in primates. J Neurochem 59:733-739.